DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
当前地点:
>
> This Story


注册记数器 to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

Tc-99m generator production resumes in Australia Follows month and a half shutdown due to conveyor belt issue

Cerveau Technologies to expand production network for research on novel tau imaging agent Understanding Alzheimer's with [18F]MK-6240

Sotera Health's Nordion closes sale of medical isotopes business to BWX Technologies About 150 employees will be transferred in the deal

GE Healthcare, Lantheus start second Flurpiridaz phase 3 clinical trial Evaluating PET agent's ability to detect CAD

New technologies to help expand PET/CT imaging in emerging markets Insights from Rick Rippin, sales director for ABT Molecular Imaging

RadioMedix and ITM greenlight Ge-68/Ga-68 generator production at new Texas facility Reducing global shortage of Ge-68/Ga-68 generators

First order of NorthStar's RadioGenix System in the books Comes alongside FDA clearance of its Wisconsin facility

SNMMI and others urge Congress to approve $20 million for U.S. supply of Mo-99 Funding would be provided for NNSA's medical isotope program

Low-risk patients subject to costly, unnecessary breast imaging, says study Ranges from $2,000 to $8,000, creates high-deductible burdens

ITM enters North American partnerships to establish stable n.c.a.-Lutetium-177 supply Enhance use and supply for targeted radionuclide therapy

Rat brain 11C-Me-NB1 PET images
superimposed on an MRI template
Courtesy of ETH Zurich

New PET imaging agent may help guide treatment for neurodegenerative diseases

Lauren Dubinsky , Senior Reporter
Swiss and German researchers have created a new PET imaging agent that may help guide and assess treatments for people with neurological diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis.

“Our new PET radioligand, 11C-Me-NB1, binds to the GluN2B sub-units of the iontropic N-methyl-D-aspartate (NMDA) receptor, for which no suitable PET imaging agent exists despite intensive research,” Simon M. Ametamey of the Institute of Pharmaceutical Sciences, ETH Zurich in Switzerland, told HCB News.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



The NMDA receptor is known to be involved in physiological processes such as learning and memory as well as various acute and chronic neurodegenerative diseases. The availability of 11C-Me-NB1 would allow researchers to study NMDA expression in healthy and diseased human brains and also help with therapy monitoring.

Ametamey and his team conducted a preclinical study that used 1C-Me-NB1 in live rats to investigate the dose and effectiveness of of a drug called eliprodil that blocks the NMDA GluN2B receptor.

The results, which were published recently in The Journal of Nuclear Medicine, demonstrated that the PET scans with the new imaging agent successfully showed that the receptors are fully occupied at neuroprotective doses of eliprodil.

“Administering patients with the right dose of the drugs is essential for minimizing side effects, which are often observed with NMDA drugs when not appropriately dosed,” said Ametamey. “Ultimately this would lead to a reduction in attrition rate and improvement in efficacy of drugs targeting the GluN2B sub-units of the NMDA receptor.”

When asked if 11C-Me-NB1 will eventually become the standard for assessing treatments for patients with neurodegenerative diseases, Ametamey said that it’s difficult to determine, since a clinical study hasn’t been conducted yet.

“Nonetheless, I anticipate that this new imaging agent, even if it doesn’t become the standard, will be used as an imaging tool to complement existing imaging agents used for assessing treatment outcomes for patients with Alzheimer’s, Parkinson’s and MS, among others,” he added.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

做广告
提升您的品牌知名度
拍卖+私人销售
获得最好的价格
买设备/配件
找到最低价格
每日新闻
阅读最新信息
目录
浏览所有的DOTmed用户
DOTmed上的伦理
查看我们的伦理计划
金子分开供营商节目
接收PH要求
金子服务经销商节目
接收请求
提供保健服务者
查看所有的HCP(简称医疗保健提供商)的工具
工作/训练
查找/申请工作
Parts Hunter +EasyPay
获取配件报价
最近证明
查看最近通过认证的用户
最近额定
查看最近通过认证的用户
出租中央
租用设备优惠
卖设备/配件
得到最划算
服务技术员论坛
查找帮助和建议
简单的征求建议书
获取设备报价
真正商业展览
查找对设备的服务
对这个站点的通入和用途是受期限和条件我们支配 法律公告 & 保密性通知
物产和业主对 DOTmed.com,公司 Copyright ©2001-2018 DOTmed.com, Inc.
版权所有